Top

Published in:

01-12-2013 | Laboratory Investigation

MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression

Authors: Yuwen Song, Luyan Mu, Xuezhe Han, Qingla Li, Baijing Dong, Hulun Li, Xiaoqian Liu

Published in: Journal of Neuro-Oncology | Issue 3/2013

Abstract

The purpose of this study was to investigate the functions of microRNA-9, which is a tissue-specific microRNA in central nervous system, in the vasculogenic mimicry (VM) of glioma cell lines in vitro and in vivo.Glioma cell lines U87MG, U251 and SHG44 were transfected with microRNA-9 mimic, microRNA-9 inhibitor or scramble sequences. The amount of microRNA-9 and Stathmin (STMN1) mRNA was determined by quantitative real-time PCR, and the protein expression of STMN1 was determined by western blot. Cell proliferation and apoptosis were assessed. The interactions between the 3′UTR of STMN1 and miR-9 was determined by luciferase reporter assay. The VM capacity in vitro was evaluated using VM formation assay, and the rescue experiment of STMN1 was carried out in U251 cells. The in vivo experiment was applied with animal models implanted with U87MG cells.MicroRNA-9 mimic transfection reduced proliferation and increased apoptosis in glioma cell lines (p < 0.05). MicroRNA-9 mimic up-regulated STMN1 mRNA levels but reduced its protein levels (p < 0.05), and luciferase activity of STMN1 was suppressed by microRNA-9 mimic transfection (p < 0.05). Furthermore, microRNA-9 mimic transfection suppressed tumor volume growth, as well as VM both in vitro and in vivo. The cell viability and microtube density were upregulated in U251 cells after STMN1 up-regulation (p < 0.05). STMN1 is a target of microRNA-9, and microRNA-9 could modulate cell proliferation, VM and tumor volume growth through controlling STMN1 expression. MicroRNA-9 and its targets may represent a novel panel of molecules for the development of glioma treatment.

Available only for authorised users

Rubin CI, Atweh GF (2004) The role of Stathmin in the regulation of the cell cycle. J Cell Biochem 93:242–250PubMedCrossRef

Bhat KM, Setaluri V (2007) Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 13:2849–2854PubMedCrossRef

Leibl S, Zigeuner R, Hutterer G et al (2008) EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS 116:27–32PubMedCrossRef

Cassimeris L (2002) The oncoprotein 18/Stathmin family of microtubule destabilizers. Curr Opin Cell Biol 14:18–24PubMedCrossRef

Rana S, Maples PB, Senzer N et al (2008) Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 8:1461–1470PubMedCrossRef

Dong B, Mu L, Qin X et al (2012) Stathmin expression in glioma-derived microvascular endothelial cells: a novel therapeutic target. Oncol Rep 27:714–718PubMed

Iorio MV, Croce CM (2009) MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27:5848–5856PubMedCrossRef

Omura N, Li CP, Li A, Hong SM et al (2008) Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 7:1146–1156PubMedCrossRef

Bandres E, Agirre X, Bitarte N et al (2009) Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 125:2737–2743PubMedCrossRef

10.

Hildebrandt MA, Gu J, Lin J et al (2010) Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29:5724–5728PubMedCrossRef

11.

Krichevsky AM, King KS, Donachue CP et al (2003) A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9:1274–1281PubMedCrossRef

12.

Krichevsky AM, Sonntag KC, Isacson O et al (2006) Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells 24:857–864PubMedCrossRef

13.

Delaloy C, Gao FB (2010) A new role for microRNA-9 in human progenitor cells. Cell Cycle 15:2913–2914CrossRef

14.

Delaloy C, Liu L, Lee JA et al (2010) MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors. Cell Stem Cell 4:323–335CrossRef

15.

Shibata M, Kurokawa D, Nakao H et al (2008) MicroRNA-9 #odulates Cajal-Retzius cell differentiation by suppressing Foxg1 expression in mouse medial pallium. J Neurosci 41:10415–10421CrossRef

16.

Li Y, Wang F, Lee JA et al (2006) MicroRNA-9a ensures the precise specification of sensory organ precursors in Drosophila. Gene Dev 20:2793–2805PubMedCrossRef

17.

Otaegi G, Pollock A, Hong J et al (2011) MicroRNA miR-9 modifies motor neuron columns by a tuning regulation of FoxP1 levels in developing spinal cords. J Neurosci 3:809–818CrossRef

18.

Bonev B, Pisco A, Papalopulu N (2011) MicroRNA-9 reveals regional diversity of neural progenitors along the anterior-posterior axis. Dev Cell 1:19–32CrossRef

19.

Holmfeldt P, Sellin ME, Gullberg M (2009) Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization. Cell Mol Life Sci 66:3263–3276PubMedCrossRef

20.

Ingber D, Prusty D, Zhengqi S et al (1995) Cell shape, cytoskeletal mechanics and cell cycle control in angiogenesis. J Biomech 28:1471–1484PubMedCrossRef

21.

Petrovic V, Costa RH, Lau LF et al (2008) FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin to promote cell cycle progression. J Biol Chem 283:453–460PubMedCrossRef

22.

Kouzu Y, Uzawa K, Koike H et al (2006) Overexpression of Stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 94:717–723PubMed

23.

Yuan RH, YM J, Chen HL et al (2006) Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209:549–558PubMedCrossRef

24.

Ghosh R, Gu G, Tillman E et al (2007) Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 67:1038–1052PubMedCrossRef

25.

Wang R, Dong K, Lin F et al (2007) Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated down- regulation of Stathmin expression. Mol Med 13:567–575PubMedCrossRef

26.

Alli E, Yang JM, Hait WN (2007) Silencing of Stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26:1003–1012PubMedCrossRef

27.

Johnsen JI, Aurelio ON, Kwaja Z et al (2000) p53-mediated negative regulation of Stathmin/Op18 expression is associated with G2/M cell-cycle arrest. Int J Cancer 88:685–691PubMedCrossRef

28.

Ngo TT, Peng T, Liang XJ et al (2007) The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 99:639–652PubMedCrossRef

29.

Liang XJ, Choi Y, Sackett DL et al (2008) Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. Cancer Res 68:5267–5272PubMedCrossRef

30.

Wong QW, Lung EW, Law PT et al (2008) MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin 1. Gastroenterology 135:257–269PubMedCrossRef

31.

Wang J, Gu Z, Ni P et al (2011) NF-kappaB P50/P65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res 15:6440–6455CrossRef

32.

Myatt S, Wang J, Monteiro L et al (2010) Definition of microRNAs that repression expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70:367–377PubMedCrossRef

33.

Ma L, Young J, Prabhala H et al (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Mat cell Biol 3:247–256

34.

Luo H, Zhang H, Zhang Z et al (2009) Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res 28:82PubMedCrossRef

35.

Wan H, Guo L, Liu T et al (2010) Regulation of the transcription factor NF-kB1 by micro RNA-9 in human gastric adenocarcinoma. Mole Cancer 9:16CrossRef

36.

Laios A, O’Toole S, Flavin R et al (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mole Cancer 7:35CrossRef

37.

Arora H, Qureshi R, Jin S et al (2011) miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFkappaB1. Exp Mole Med 5:298–304CrossRef

38.

Nass D, Rosenwald S, Meiri E et al (2009) MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 19:375–383PubMedCrossRef

39.

Jeon H, Sohn Y, Oh S et al (2011) ID4 Imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res 9:3410–3421CrossRef

40.

Schraivogel D, Weimann L, Beier D et al (2011) CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBOJ 20:4309–4322CrossRef

41.

Ben-Hamo R, Efroni S (2011) Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression. Genome Med 3(11):77PubMedCrossRef

42.

Chao T, Zhang Y, Yan X et al (2008) Mir-9 regulates the expression of CBX7 in Human Glioma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 30:268–274PubMed

43.

Maniotis AJ, Folberg R, Hess A et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739–752PubMedCrossRef

44.

Folberg R, Maniotis AJ (2004) Vasculogenic mimicry. APMIS 112:508–525PubMedCrossRef

45.

Wang S, Yu L, Ling G et al (2012) Vasculogenic mimicry and its clinical significance in medulloblastoma. Cancer Biol Ther 5:341–348

46.

Chen Y, Jing Z, Luo C et al (2012) Vasculogenic mimicry-potential target for glioma therapy: an in vitro and in vivo study. Med Oncol 29:324–331PubMedCrossRef

Title: MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression
Authors: Yuwen Song
Luyan Mu
Xuezhe Han
Qingla Li
Baijing Dong
Hulun Li
Xiaoqian Liu
Publication date: 01-12-2013
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1245-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study

Cortical hemosiderin is associated with seizures in patients with newly diagnosed malignant brain tumors

Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features

Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis